Thursday, March 2, 2017 - 07:00
  • Reinforcing safety profile of monalizumab and rationale for broad ability to combine with other anticancer agents

Innate Pharma SA (the “Company” - Euronext Paris: FR0010331421 – IPH) today announces that data on monalizumab will be presented at the American Association for Cancer Research (AACR) Annual Meeting, April 1 - 5, 2017, in Washington, D.C. Abstracts are available on the AACR website. Monalizumab is Innate Pharma’s investigational first-in-class anti-NKG2A antibody partnered with AstraZeneca.

These data support the rationale for the development of monalizumab:

  • Preclinical data will be presented in a mini-symposium and show NKG2A expression on tumor-infiltrating CD8+ T cells in patients with head and neck cancer as well as synergy between treatment with a HPV vaccine and NKG2A blockade in a mouse tumor model;
  • During a poster session, safety data from the dose-escalation part of a Phase Ib/II study evaluating monalizumab in combination with cetuximab in patients with recurrent or metastatic squamous cell carcinoma of the head and neck will be presented. In this study, monalizumab plus cetuximab were well tolerated with no additional safety concerns compared to monalizumab or cetuximab alone.

Monalizumab is currently being tested in five Phase I and I/II clinical trials in various cancer as a single agent and in combination with other therapies.


Presentation and poster details:

  • NKG2A checkpoint receptor expression on tumor-infiltrating CD8+ T cells restrains efficacy of immunotherapy
    • Abstract Number: 2999 
    • Session Type: Mini-symposium, webcast
    • Session Title: Innate Immune Mechanisms in Cancer Treatment
    • Session Date and Time: Monday April 3, 2017 4:35 – 4:50 PM EST
    • Location: Washington Convention Center, Room 152, Level 1
    • Presented by Thorbald van Hall, Department of Clinical Oncology, Leiden University Medical Centre, The Netherlands
  • Safety of the first-in-class anti-NKG2A monoclonal antibody monalizumab in combination with cetuximab: a phase Ib/II study in recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN)
    • Abstract Number: 5666/20 
    • Session Type: Poster Session
    • Session Title: Innate Immunity to Generate Adaptive Immunity
    • Session Date and Time: Wednesday April 5, 2017 8:00 AM - 12:00 PM EST
    • Location: Washington Convention Center, Halls A-C, Poster Section 28
    • Presented by Roger B. Cohen M.D., Abramson Cancer Center, Philadelphia, USA